Emerging evidence point toward SIRT7 as a therapeutic target for human cancer management because inactivate SIRT7 results in impairment of cancer transformation, increases chemosensitivity, and reverses metastatic phenotypes in both epithelial and mesenchymal tumors (Malik et al., 2015; Monteiro-Reis et al., 2020; Zhao et al., 2020). Here, SIRT7 is linked to mesenchymal cell neoplasm.